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Parallel advances in neuroscience and immunology established the anatomical and cellular basis for bidirec-
tional interactions between the nervous and immune systems. Like other physiological systems, the immune
system—and the development of immunity—is modulated by neural reflexes. A prototypical example is the
inflammatory reflex, comprised of an afferent arm that senses inflammation and an efferent arm, the cholin-
ergic anti-inflammatory pathway, that inhibits innate immune responses. This mechanism is dependent on
the a7 subunit of the nicotinic acetylcholine receptor, which inhibits NF-kB nuclear translocation and
suppresses cytokine release by monocytes and macrophages. Here we summarize evidence showing that
innate immunity is reflexive. Future advances will come from applying an integrative physiology approach
that utilizes methods adapted from neuroscience and immunology.Reflex Control of Immunity
Immunity can be innate, occurring when molecular products
derived from pathogens or injured cells activate cytokine
production from monocytes and macrophages, or adaptive,
the specific and long-lasting response of lymphocytes based
on prior exposure to antigen. Cytokines released during innate
immunity mediate inflammation, producing the cardinal signs
of swelling, pain, erythema, and fever. This response is usually
short-lived, and inflammation resolves. In some cases, however,
cytokine production can become excessive, and rather than
resolving, inflammation persists or even spreads, causing
damage in adjacent tissues. This is the basis for the ‘‘cytokine
theory of disease,’’ the paradigm that cytokines are necessary
and sufficient for disease pathogenesis (Tracey, 2007). This is
axiomatic for modern therapeutic approaches to rheumatoid
arthritis, inflammatory bowel disease, and other inflammatory
diseases that are significantly ameliorated by treatment with
drugs that selectively target cytokines (e.g., anti-TNF and anti-
IL-1b therapies) to the benefit of millions of patients.
Recent advances in fundamental neuroscience have provided
an answer to the critical question raised by the cytokine theory of
disease. If cytokines mediate pathophysiological damage, do
neural reflexes regulate cytokine production to maintain homeo-
stasis? The answer stems from studies addressing the role of
neural networks, which revealed that signals originating in the
brain, and conveyed as action potentials transmitted in the
vagus nerve, regulate cytokine production by the innate immune
system (Tracey, 2009). This neural circuit, termed the cholinergic
anti-inflammatory pathway, is mediated by the vagus nerve and
the a7 subunit of the nicotinic acetylcholine receptor expressed
on cytokine-producing cells (Wang et al., 2003). Activation of this
pathway by electrical stimulation of the vagus nerve or adminis-
tration of a7 selective drugs is effective in ameliorating inflamma-
tion and improving survival in experimental models of sepsis
(Borovikova et al., 2000; Pavlov et al., 2007; Wang et al., 2004),
hemorrhagic shock (Guarini et al., 2003), pancreatitis (van West-28 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.erloo et al., 2006), postoperative ileus (The et al., 2007), and
endothelial cell activation (Saeed et al., 2005).
Nicotinic receptors are ligand-gated ion channels comprising
a family of hetero- or homopentameric structures derived from
the products of 17 genes (Millar, 2003). In brain neurons, a7 is
a homopentameric calcium channel expressed predominantly
in presynaptic nerve terminals where it modulates neurotrans-
mitter release, and in postsynaptic neurons where it induces
excitatory impulses. Signaling through a7 in the central nervous
system is associated with neuronal plasticity and cell survival
(Berg and Conroy, 2002; Drisdel and Green, 2000). In macro-
phages, signaling through a7 attenuates TNF production through
a mechanism dependent upon inhibition of NF-kB nuclear trans-
location and activation of Jak-STAT pathways (Borovikova et al.,
2000; de Jonge et al., 2005; Parrish et al., 2008).
Experiments addressing the anatomical basis of the cholin-
ergic anti-inflammatory pathway indicated that the spleen is
the target organ of the vagus nerve for controlling TNF produc-
tion (Huston et al., 2006). Further studies identifiedmacrophages
as the cell source of spleen TNF and showed that the splenic
nerve is required for vagus nerve stimulation to suppress
systemic TNF levels. A two-neuron system comprised of the
vagus nerve and the splenic nerve, via the celiac ganglion,
conveys signals from the brain to the immune cells residing in
the spleen (Rosas-Ballina et al., 2008).
The requirement for a functional splenic nerve in the cholin-
ergic anti-inflammatory pathway is noteworthy because it is
primarily composed of catecholaminergic nerve fibers (Klein
et al., 1982). In fact, ablation of catecholamines by treatment
with reserpine abrogates the suppressive effect of vagus nerve
stimulation (Rosas-Ballina et al., 2008). It is clear that a7 signal
transduction is required for the control of cytokine release by
monocytes and macrophages in vitro and that the cholinergic
anti-inflammatory pathway requires a7 signaling to control cyto-
kine production in vivo. It is possible that acetylcholine released
by the vagus nerve signals through a7, which is expressed in the
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requirement for a7 expression to control cytokine production
in vitro. An alternative explanation is based on the decades old
observations that the spleen contains acetylcholine and that
electrical stimulation of the splenic nerve mediates acetylcholine
release in spleen (Dale and Dudley, 1929; Leaders and Dayrit,
1965). Since the spleen lacks cholinergic nerve fibers (Bellinger
et al., 1993), acetylcholine in spleen may be derived from
lymphocytes and other immune cells that synthesize and release
acetylcholine located in the vicinity of nerve endings (Grando
et al., 1993; Kawashima and Fujii, 2004; Wessler and Kirkpatrick,
2001). This may explain how electrical stimulation of the vagus
nerve can induce acetylcholine release in spleen, which in turn
regulates cytokine release through a7 expressed on responding
cells.
The sensory armof the inflammatory reflex can be activated by
the presence of IL-1b in peripheral tissues. Specific IL-1b binding
sites have been revealed on glomus cells adjacent to the vagus
nerve (Goehler et al., 1997). IL-1b binding and an intact vagus
nerve are both required for the development of fever following
intraperitoneal administration of low quantities of IL-1b (Maier
et al., 1998). Administration of larger amounts of IL-1b bypasses
this mechanism and directly activates the fever response by
directly binding to hypothalamic neurons (Hansen et al., 2001).
The sensory arm of the inflammatory reflex represents a crucial
early detection system that activates a conserved set of neuro-
physiological responses, including fever, anorexia, and behav-
ioral withdrawal characteristic of sickness behavior. It can also
activate opposing effector responses that suppress ongoing
inflammation through at least two anti-inflammatory routes: (1)
via activation of the hypothalamic pituitary axis and increasing
corticosteroid hormone levels (Butts and Sternberg, 2008) and
(2) via activation of the cholinergic anti-inflammatory pathway
(Figure 1).
Innervation of Lymphoid Organs
Bone marrow, thymus, lymph nodes, and spleen are all inner-
vated by fibers of the autonomic nervous system that utilize
a range of neurotransmitters. This is the anatomical and func-
tional basis of interactions between nerves and immune cells
(reviewed in Mignini et al., 2003). Accumulating evidence indi-
cates that innervation of lymphoid organs is not a static phenom-
enon. Rather, the number of nerve endings and their distribution
within immune organs undergoes a dynamic process of remod-
eling that is modulated in part by immune cell function. For
example, subcutaneous injection of antigen is associated with
increased nerve ending density in the medulla of the draining
lymph node, particularly at the declining phase of antibody
production. This augmented nerve fiber density occurs specifi-
cally in the parenchyma of the medulla, while nerve fibers asso-
ciated with the lymph node’s vasculature remain unchanged
(Novotny et al., 1994). Mouse spleen injected with tuberculin
shows increased numbers of nerve ending branches and richer
nerve varicosities (Yang et al., 1998). SCID mice, which lack
functional B and T cells, have increased numbers of nerve end-
ings around central arteries and reduced numbers in the white
pulp parenchyma of spleen. Adoptive transfer of T cells restores
the normal pattern through a mechanism dependent in part onIL-3 release, indicating that immune cells modulate neural
network formation (Kannan-Hayashi et al., 2008). Nude mice,
which lack functional T cells, have a higher density of nerve fibers
in spleen, and adoptive transfer of T cells into these mice
reduces spleen catecholaminergic load (Besedovsky et al.,
1987). In addition, coculture studies indicate that neurons selec-
tively establish andmaintain contacts with immune cells and that
cytokines such as IL-3 and IL-6, and GM-CSF and NGF derived
from immune cells promote neurite expansion (Kannan et al.,
1994, 1996, 2000). It is plausible that other factors, including
integrins and adhesion molecules, contribute to establishing
and maintaining nerve and immune cell interactions. Together,
these and other results implicate the immune system in modu-
lating its own neural input.
Nerve remodeling in immune organs has been observed in
both physiologic and pathological conditions. Splenic nerve
endings increase in number in the hilar region of the spleen
and decrease in spleen zones opposite to the hilus in a model
of rat adjuvant-induced arthritis. As disease progresses, nerve












Figure 1. The Inflammatory Reflex
Control systems orchestrated by the autonomic nervous system (e.g., heart
rate control) integrate input signals and deliver responses that modify bodily
function according to changing physiologic demands. Similarly, cytokines
produced by immune cells in response to endogenous and exogenous stimuli
activate afferent neurons of the vagus nerve that conveys this information to
the brain where signal integration occurs. A response is elicited through the
cholinergic anti-inflammatory pathway, the efferent arc of this inflammatory
reflex, which modifies immune function and maintains homeostasis. The
cholinergic anti-inflammatory pathway conveys signals from the brain to
the spleen via the vagus nerve and the splenic nerve and is dependent on
the a7 subunit of the nicotinic acetylcholine receptor.Neuron 64, October 15, 2009 ª2009 Elsevier Inc. 29
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reduction in spleen nerve fibers was observed in a model of
collagen-induced arthritis in mice, which was accompanied by
changes in spleen cytokine release (Straub et al., 2008). On the
one hand, nerves convey information to immune cells andmodu-
late their responses (for examples see Antonica et al., 1996;
Besedovsky et al., 1979; Esquifino et al., 2001); on the other,
immune cell activity reshapes the number and anatomical distri-
bution of nerve endings and modulates their neurotransmitter
content. The nervous system thus maintains a reciprocal and
functional interaction with immune cells residing in lymphoid
organs through dynamic remodeling of nerve endings.
Nerve Plasticity in Lymphoid Organs
Plasticity in neuroscience is the ability of neural synapses to
modify connection strength depending upon experience. It is
plausible that nerve endings in lymphoid organs, which contract
and expand, in part in response to signals originating from target
cells, can be thought of as ‘‘plastic.’’ Then, what is the relevant
‘‘experience’’ or ‘‘behavior’’ driving neural plasticity in lymphoid
organs? Is nerve plasticity in lymphoid organs a manifestation
of sensitization and desensitization phenomena intrinsic to the
inflammatory reflex?
Neuroscience has investigated the molecular mechanism of
nonassociative learning and its functional consequence in short-
and long-term sensitization. When a noxious stimulus is applied
to the tail of Aplysia, a gill-withdrawal reflex is produced. This
response becomes greater when the stimulus is repeated and
short-term sensitization lasts for minutes. Repeatedly stimu-
lating at regular intervals produces long-term sensitization,
which lasts for days (Castellucci et al., 1986). This elementary
form of implicit memory requires new protein synthesis and the
growth of new synapses (Bailey and Chen, 1983; Castellucci
et al., 1989). We propose that it should be possible to study
the effect of stimulating single neurons, once or repeatedly,
and measure the function of immune cell activity. Nerve stimula-
tion (e.g., vagus nerve stimulation) could be coupled with
recording of immune cell function to make observations about
the development of neuroimmune plasticity (Figure 2).
An obvious impediment to implementing this technique is that
immune cells, in contrast to neurons andmuscle, are not studied
as excitable cells. Immune cells do express ion channels that
modulate membrane potential and calcium signaling. Antigenic
stimulation of T cells through the TCR/CD3 complex releases
Ca2+ from the endoplasmic reticulum (ER). Increased intracel-
lular calcium is then followed by transcription factor NF-AT
activation, a process mediated by calcineurin. Release of Ca2+
from ER is not sufficient to initiate gene transcription, and
long-lasting elevated Ca2+ concentrations maintained by ion
channels expressed on the T cell plasmamembrane are required
for full activation of the signaling cascade (Krasznai, 2005;
Panyi et al., 2004). For example, the Ca2+ release-activated
Ca2+ (CRAC) channel and the voltage-gated Kv1.3 channel are
involved in T cell activation and proliferation, and their expres-
sion depends on state of activation and differentiation (Chandy
et al., 1984; DeCoursey et al., 1984; Nagy et al., 1995; Panyi
et al., 2004). Drugs that selectively block channel function in
T cells are effective in improving the clinical course in experi-30 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.mental models of multiple sclerosis and delayed type hypersen-
sitivity (Beeton et al., 2001; Matheu et al., 2008). Moreover,
neurotransmitters can affect membrane potential and ion
channel function in lymphocytes. Acetylcholine exerts depolariz-
ing and K+ channel blocking effects in lymphocytes and reduces
the proliferative response to PHA (Gaspar et al., 1996); and
b adrenergic stimulation modulates voltage-dependent K+
conductance in CD8 lymphocytes (Soliven and Nelson, 1990).
Thus, it is reasonable to hypothesize that neurotransmitter
release elicited by nerve stimulation can translate into measur-
able changes in membrane potential, calcium signaling, and
altered immune cell function.
A similar approach could be used to study the long-term effect
of neurotransmitters on macrophage membrane potential,
calcium signaling, and cytokine production. Macrophages
obtained from calcium-activated potassium channel KCa3.1
knockout mice show decreased activation, and administration
of selective blockers diminishes macrophage migration to aortic
plaques in a mouse model of atherosclerosis (Toyama et al.,
2008). Furthermore, patch-clamp analysis shows that transient
membrane depolarization in macrophages is accompanied by
increased IL-6 transcription when stimulated with ATP (Hanley
et al., 2004), which is released from catecholaminergic nerve
endings (Sneddon and Westfall, 1984). We have found that
macrophages incubated with acetylcholine for 60 min retain an
immunosuppressed phenotype for as long as 2 days, such that
subsequent stimulation with endotoxin even 48 hr after exposure
to acetylcholine is associated with persistently low TNF produc-
tion (Huston et al., 2007). The in vivo correlate of this observation





Figure 2. Experimental Model for Studying Neuroimmune Plasticity
Transmission of neural signals to immune cells in lymphoid organs is a dynamic
process involving remodeling of nerve fibers. Cells of the immune system are
likely exposed to constant fluctuation in neurotransmitter concentration in their
microenvironment as a result of second-to-second changes in nerve firing
rate. Studying the effects of nerve firing frequency on immune cell function
using electrophysiology together with assessment of immune function could
reveal habituation and sensitization phenomena underlying nerve-to-immune
cell interactions. The figure depicts a hypothetical two-cell culture system
showing different activity states of a neuroimmune synapse. The number
and frequency of synapses and the magnitude of the immune response
would vary depending on whether the system is at rest, habituated, or under
sensitization.
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TNF response 48 hr after the vagus nerve is electrically stimu-
lated (Huston et al., 2007). Studying the effect of nerve pulse
frequency and neurotransmitter release on macrophage cyto-
kine production should also be utilized to address whether
macrophages develop neural-induced sensitization or desensiti-
zation.
Neural Control of Immune Memory
It has been suggested that afferent fibers can ‘‘sense’’ antigen in
collaboration with dendritic cells and contribute to the early
development of adaptive immunity. Rats sensitized with hapten
administered to the abdomen develop an inflammatory response
in the ear when the same hapten is later administered to the ear.
This response requires antigen presentation to T cells in the
abdominal lymph node and the establishment of immunological
memory. Denervation of either the abdominal tissue or the ear
prevents the inflammatory response in the ear, but does not alter
the development of immune memory to antigen (Beresford et al.,
2004). This indicates that immunememory occurs without neural
input but that neural networks are required for mobilization of
T cells from the abdominal lymph node to the challenged area.
It is possible that in the contact sensitivity model, antigen expo-
sure creates immunologic memory that is specific to the antigen
and neural memory that is required to recall prior antigen expo-
sure (Shepherd et al., 2005). It is plausible that immune cells
communicate with afferent neurons via cytokines or other medi-
ators (Goehler et al., 1998; Uceyler et al., 2009; Weinreich and
Undem, 1987) to establish neuroimmune connections encoding
previous inflammatory and antigenic experience. Understanding
nerve plasticity at the site where immune responses occur,
perhaps by studying the effect of immune cell activity on sensory
neurons in vitro, could reveal neural networks that establish and
maintain immunological memory.
Concluding Remarks
The immune system is no longer regarded as autonomous. It is
a distributed system that exhibits complex behavior orches-
trated by neural networks and reflexes. Certain, if not all, aspects
of innate and adaptive immunity require neural systems to
manifest the full range of coordinated, physiological, and immu-
nological responses that underlie homeostasis. The cholinergic
anti-inflammatory pathway is but an example of a well-charac-
terized neural circuit that controls inflammation through a highly
integrated physiological system. Electrical stimulation of the
vagus nerve, a new therapeutic approach to attenuate inflamma-
tion, takes advantage of the neuroanatomical circuitry to deliver
anti-inflammatory signals to discrete cells in specific organs.
Advances in this field will undoubtedly reveal other neural
networks that coordinate immunity by enhancing or suppressing
immune responses via specific molecular mechanisms. We
believe that the time has come for studying the interdependent
activities of neural and immune cells using an integrative physi-
ologic approach with technical methods adopted from neurosci-
ence. Selective in vivo and in vitro stimulation of nerves or
neurons in conjunction with electrophysiological measurement
of immune cell activity and vice versa will provide new insights
into the cellular and molecular basis of the interplay betweennerves and immune cells and its contribution to physiological
homeostasis during infection and injury.
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